Artelo Biosciences (ARTL) announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine cocrystal. The peer-reviewed study, conducted in collaboration with researchers at Western Ontario University, was published in Progress in Neuro-Psychopharmacology and Biological Psychiatry and highlighted that ART12.11 significantly outperformed cannabidiol alone in reducing stress-induced depression and anxiety symptoms, while also achieving superior oral bioavailability. Key Findings: Enhanced Efficacy: ART12.11 reversed stress-induced behavioral deficits and produced robust anti-depressant and anxiolytic-like effects. These benefits were superior to CBD alone, TMP alone, or a non-crystalline mixture of CBD and TMP. Improved Bioavailability: Oral administration of ART12.11 resulted in higher plasma concentrations of CBD and its major metabolite, highlighting improved pharmacokinetic properties over conventional CBD formulations. Mechanistic Insights: ART12.11 enhanced activation of the endocannabinoid and serotonergic systems in brain regions critical to mood regulation, including the prefrontal cortex, ventral hippocampus, and nucleus accumbens.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Updates Bylaws on September 9, 2025
- Alphabet downgraded, Boeing upgraded: Wall Street’s top analyst calls
- Artelo Biosciences downgraded to Hold from Buy at D. Boral Capital
- Artelo prices 640,924 shares at $4.40 in underwritten public offering
- Artelo Biosciences announces common stock, warrant offering, no amount given